Drug intelligence / Profile preview

ZF887

Development stage: Discontinued
Lead developer: Centessa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

ZF887 is a **small molecule chemical chaperone** developed as a folding corrector for the Z variant of alpha-1-antitrypsin (Z-A1AT), intended for treatment of alpha-1-antitrypsin deficiency. Its mechanism involves correcting misfolded Z-A1AT protein to normalize protein levels and potentially address both liver and lung manifestations of the disease. ZF887 was advanced to preclinical development, with Centessa Pharmaceuticals acquiring/continuing its development from Z Factor Ltd., but development was discontinued before reaching clinical trials[1][3][5][13][14].

Other names: ZF887ZF-887ZF 887

Targets

SERPINA1 Z (Alpha-1-antitrypsin Z variant protein)

Beyond the preview

Go deeper on ZF887.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZF887.

Explore the full profile